Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
TORONTO and HOUSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as
(Financial Post, 2025-10-01T11:00:41Z)